Novartis AG $NVS Stock: Keybank National Association OH Trims Holdings

Keybank National Association OH decreased its position in Novartis AG (NYSE:NVS) by 25.5% during the 3rd quarter, according to the company in its most recent filing with the SEC. The fund owned 53,448 shares of the company’s stock after selling 18,276 shares during the quarter. Keybank National Association OH’s holdings in Novartis were worth $7,620,000 at the end of the most recent reporting period.

Other hedge funds have also made changes to their positions in the company. Csenge Advisory Group increased its position in shares of Novartis by 6.7% during the 3rd quarter. Csenge Advisory Group now owns 17,186 shares of the company’s stock worth $2,450,000 after purchasing an additional 1,076 shares in the last quarter. Gen Wealth Partners Inc acquired a new position in Novartis in the third quarter valued at about $30,000. Kestra Investment Management LLC boosted its position in Novartis by 6.4% in the third quarter. Kestra Investment Management LLC now owns 2,167 shares of the company’s stock valued at $309,000 after buying an additional 130 shares in the last quarter. Allspring Global Investments Holdings LLC boosted its position in Novartis by 2.1% in the third quarter. Allspring Global Investments Holdings LLC now owns 82,309 shares of the company’s stock valued at $11,610,000 after buying an additional 1,696 shares in the last quarter. Finally, Beverly Hills Private Wealth LLC grew its stake in Novartis by 19.2% during the third quarter. Beverly Hills Private Wealth LLC now owns 3,094 shares of the company’s stock worth $441,000 after buying an additional 498 shares during the last quarter. Institutional investors and hedge funds own 13.12% of the company’s stock.

Novartis Stock Down 0.1%

Shares of NYSE NVS opened at $160.16 on Friday. The firm’s 50-day simple moving average is $149.18 and its 200 day simple moving average is $152.56. The company has a market cap of $305.61 billion, a price-to-earnings ratio of 30.56, a price-to-earnings-growth ratio of 2.93 and a beta of 0.40. The company has a quick ratio of 0.70, a current ratio of 0.88 and a debt-to-equity ratio of 0.98. Novartis AG has a 12-month low of $123.24 and a 12-month high of $170.46.

Novartis (NYSE:NVS) last issued its quarterly earnings data on Tuesday, October 27th. The company reported $2.46 EPS for the quarter, topping analysts’ consensus estimates of $2.25 by $0.21. The firm had revenue of $15.03 billion for the quarter, compared to analyst estimates of $14.53 billion. Novartis had a net margin of 18.11% and a return on equity of 41.04%. The company’s revenue was up 4.4% on a year-over-year basis. During the same quarter in the prior year, the firm earned $2.25 EPS. On average, research analysts expect that Novartis AG will post 9.10 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

NVS has been the topic of several research analyst reports. UBS Group reaffirmed a “neutral” rating on shares of Novartis in a research note on Wednesday, October 28th. Morgan Stanley reiterated an “overweight” rating and issued a $163.00 target price on shares of Novartis in a research note on Wednesday, October 28th. Royal Bank Of Canada reissued a “sector perform” rating on shares of Novartis in a report on Wednesday, October 28th. JPMorgan Chase & Co. reissued a “buy” rating on shares of Novartis in a report on Sunday, August 9th. Finally, DZ Bank began coverage on Novartis in a research report on Wednesday, October 28th. They set a “hold” rating on the stock. Six analysts have rated the stock with a Buy rating, nine have issued a Hold rating and three have given a Sell rating to the company. According to data from MarketBeat, Novartis has an average rating of “Hold” and a consensus target price of $152.25.

More Novartis News

These are some of the NVS news items that stood out recently:

• Positive Sentiment: Zacks Research raised its FY2026 EPS estimate to $9.06 from $8.83 and its FY2027 estimate to $9.91 from $9.75. It also increased several quarterly forecasts, including Q3 2027 to $2.57 from $2.45. The revisions suggest improved expectations for some periods, though the FY2026 estimate is close to the cited $9.08 consensus. Zacks Research estimate revisions
• Neutral Sentiment: Novartis presented long-term ianalumab data for Sjögren’s disease. The update may draw attention to its drug pipeline, but the article information provided does not describe the results or indicate a change to the drug’s commercial outlook. Long-term ianalumab data article
• Negative Sentiment: Zacks Research trimmed its FY2028 EPS forecast to $10.62 from $10.69 and lowered estimates for some quarters, including Q1 2028 to $2.45 from $2.54. These cuts temper the positive revisions, though they are modest and concern future periods. Zacks Research estimate revisions

Novartis Company Profile

Novartis AG is a Swiss pharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative medicines. Its research and products address conditions in areas including oncology, immunology, neuroscience, and cardiovascular, renal and metabolic health. The company’s medicines include treatments such as Kisqali for certain breast cancers, Cosentyx for inflammatory diseases, Entresto for heart failure and Kesimpta for multiple sclerosis. Its portfolio also includes radioligand therapies and other specialized treatments.